The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats-Reference-Cited by-同舟云学术

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats

Published:2018-06-19 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Schwabl Philipp^ORCID,Brusilovskaya Ksenia,Supper Paul,Bauer David,Königshofer Philipp^ORCID,Riedl Florian,Hayden Hubert,Fuchs Claudia Daniela,Stift Judith,Oberhuber Georg,Aschauer Stefan,Bonderman Diana,Gnad Thorsten,Pfeifer Alexander,Uschner Frank Erhard,Trebicka Jonel,Rohr-Udilova Nataliya,Podesser Bruno Karl,Peck-Radosavljevic Markus,Trauner Michael,Reiberger Thomas^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-27656-y.pdf

Reference56 articles.

1. de Franchis, R. & Baveno, V. I. F. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of hepatology 63, 743–752, https://doi.org/10.1016/j.jhep.2015.05.022 (2015).

2. Villanueva, C. et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology 63, 197–206, https://doi.org/10.1002/hep.28264 (2016).

3. Reiberger, T. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62, 1634–1641, https://doi.org/10.1136/gutjnl-2012-304038 (2013).

4. Schwabl, P. et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver international: official journal of the International Association for the Study of the Liver 35, 2121–2128, https://doi.org/10.1111/liv.12795 (2015).

5. Reiberger, T. & Mandorfer, M. Beta adrenergic blockade and decompensated cirrhosis. Journal of hepatology 66, 849–859, https://doi.org/10.1016/j.jhep.2016.11.001 (2017).

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiology and therapeutic options for cirrhotic portal hypertension;The Lancet Gastroenterology & Hepatology;2024-07

2. Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test;Liver Transplantation;2024-06-12

3. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD;Journal of Hepatology;2024-05

4. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension;iScience;2024-03

5. Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases;Sinusoidal Cells in Liver Diseases;2024